Literature DB >> 24509302

US-guided percutaneous liver biopsy in pediatric liver transplant recipients.

Soma Mandal1, Roberto Miraglia, Luigi Maruzzelli, Rosa Liotta, Fabio Tuzzolino, Marco Spada, Silvia Riva, Angelo Luca.   

Abstract

OBJECTIVES: The present study assesses the safety of ultrasound (US)-guided percutaneous liver biopsies (PLBs) within pediatric liver allograft recipients, describes the pathological results according to early (≤12 months) and late (>12 months) posttransplantation periods, and analyzes the value of liver function tests (LFTs) and Doppler US variables in determining these results.
METHODS: A total of 219 US-guided PLBs in 85 pediatric patients with liver transplant (mean age 7 ± 5 years, range: 6 months to 18 years) performed between March 2005 and May 2012 were retrospectively evaluated at a single institution. Doppler US and LFT evaluation (including total bilirubin, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, alkaline phosphatase) occurred within 1 day of early (n = 92, 42%) and late term (n = 127, 58%) posttransplantation biopsies.
RESULTS: The rate of major complications (hemorrhage requiring blood transfusion) was 0.91% (n = 2). The early versus late term biopsy results, respectively, included: cholestasis at 36% versus 18% (P = 0.003), minimal changes 16% versus 24% (not significant [NS]), acute rejection 13% versus 5% (P = 0.027), inflammatory diseases 15% versus 15% (NS), indeterminate acute rejection 11% versus 7% (NS), chronic rejection 4% versus 14% (P = 0.017), fibrotic diseases 4% versus 12% (NS), and other 0% versus 5% (NS). Neither LFT nor US variables were correlated with pathological outcomes.
CONCLUSIONS: The rate of complications in pediatric patients after US-guided liver biopsy is low. A range of pathological results exists between early and late posttransplantation liver biopsies. LFT and Doppler US findings are not predictors of pathological results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509302     DOI: 10.1097/MPG.0000000000000328

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials.

Authors:  Emily R Perito; Mercedes Martinez; Yumirle P Turmelle; Kristen Mason; Katharine M Spain; John C Bucuvalas; Sandy Feng
Journal:  Am J Transplant       Date:  2019-02-04       Impact factor: 8.086

2.  Pediatric liver cirrhosis interventional procedures: from biopsy to transjugular intrahepatic portosystemic shunt.

Authors:  Gian Luigi Natali; Giulia Cassanelli; Guglielmo Paolantonio; George Koshy Parapatt; Lorenzo Maria Gregori; Massimo Rollo
Journal:  Pediatr Radiol       Date:  2022-09-19

3.  Clinical Value of Surveillance Biopsies in Pediatric Liver Transplantation.

Authors:  Brittany Rocque; Aaron Zaldana; Carly Weaver; Julia Huang; Arianna Barbetta; Victoria Shakhin; Cameron Goldbeck; George Yanni; Shannon Zielsdorf; Yong Kwon; Kambiz Etesami; Yuri Genyk; Shengmei Zhou; Rohit Kohli; Juliet Emamaullee
Journal:  Liver Transpl       Date:  2022-01-20       Impact factor: 6.112

4.  Major complications after percutaneous biopsy of native or transplanted liver in pediatric patients: a nationwide inpatient database study in Japan.

Authors:  Kayo Ikeda Kurakawa; Akira Okada; Kazuhiko Bessho; Taisuke Jo; Sachiko Ono; Nobuaki Michihata; Ryosuke Kumazawa; Hiroki Matsui; Kiyohide Fushimi; Satoko Yamaguchi; Toshimasa Yamauchi; Masaomi Nangaku; Takashi Kadowaki; Hideo Yasunaga
Journal:  BMC Gastroenterol       Date:  2022-08-24       Impact factor: 2.847

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.